Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer

Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer

Patient-derived xenografts (PDXs) are powerful tools for translational cancer research. Here, we established PDX models from different molecular subtypes of breast cancer for in vivo drug tests and compared the histopathologic features of PDX model tumors with those of patient tumors. Predictive bio...

Full description

Bibliographic Details
Main Authors: Jin-Sun Ryu, Sung Hoon Sim, In Hae Park, Eun Gyeong Lee, Eun Sook Lee, Yun-Hee Kim, Youngmee Kwon, Sun-Young Kong, Keun Seok Lee
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:Cancers
Subjects:
patient-derived xenograft
breast cancer
pre-clinical drug test
personalized therapy
sorafenib
everolimus
docetaxel
bevacizumab
PX-478
neratinib
Online Access:https://www.mdpi.com/2072-6694/11/4/574

Internet

https://www.mdpi.com/2072-6694/11/4/574

Similar Items